semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 2.0-9.0,  Parental/Caregiver Anxiety Child's Anxiety Pediatric patients ages 2-9 years ASA class I-II inpatient surgeries of at least 2 hours duration requiring postoperative admission of at least 23 hours  contraindication to preoperative sedation, known allergy or sensitivity to the study medications those who lack legal representative consent Patients with weights lying below the 5th percentile or above the 95th percentile according to the current published CDC growth chart will also be excluded regardless of existing specific contraindication
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Bipolar Disorder The patient was correctly informed about the study The patient must be insured or beneficiary of a health insurance plan The diagnosis of bipolar disorder is confirmed by the doctor referring the patient to the BEC and confirmed during the preliminary interview at the BEC The patient is euthymic on the day of inclusion. This is supported by a short psychiatric interview conducted at the BEC and the completion of the depression and mania scales (score <= 7 on the HDRS questionnaire and score <= 7 on the YMRS questionnaire) The patient is prescribed a mood stabilizer based on lithium or divalproex  The patient is under judicial protection, under tutorship or curatorship The patient formalizes his/her opposition to the studyd It is impossible to correctly inform the patient The patient has mental retardation The patient has practiced substance abuse or dependence within the 6 months prior to study (alcool, cannabis, opiates, psychostimulants) The patient does not meet euthymic (score <= 7 on the HDRS questionnaire and score <= 7 on the YMRS questionnaire) Uninclusion The patients withdraws consent during the study The patient does not understand directions necessary for the neurpsychological tasks The patient is not able to use a computer to complete the neuropsychological tasks
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 13.0-21.0,  Bipolar Disorder Suicidal Ideation Diagnosis of Bipolar Disorder I, Bipolar Disorder II, or Bipolar Disorder Not Otherwise Specified Living with or in close contact with at least one parent who is willing to participate Have had at least 1 week in the prior 3 months of significant suicidal ideation and/or at least one suicidal event in the 3 months prior to study intake Willing to be treated pharmacologically by a psychiatrist in the UCLA Child and Adolescent Mood Disorders (CHAMP) clinic  Participants requiring immediate hospitalization Diagnosis of borderline personality disorder, schizophrenia, or schizoaffective disorder Current substance dependence disorder
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-69.0,  Insomnia age between 18 years to 69 years fluent in German language provide written informed consent ability to understand the explanations and instructions given by the study physician and the investigator  Sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome, narcolepsy, substance-induced insomnia) Contraindications to study medication intake according to the information sheet for health professionals (Summary of medicinal Product Characteristics, SmPC; Fachinformation in Germany) assessed by physical examination (including ECG) and medical history allergies to amitriptyline hydrochloride or any of its ingredients allergies to zolpidem or any of its ingredients acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic drug urinary retention delirium untreated closed-angle glaucoma prostatic hyperplasia pyloric stenosis
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 13.0-19.0,  Insomnia Depression Between 13-19 years of age Are depressed Have insomnia  Are not depressed Do not have insomnia Currently using a sleep aid Have bipolar depression Have psychotic disorder Have a sleep disorder other than insomnia
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Ability to understand and the willingness to sign a written informed consent form Subjects with histologically confirmed local adenocarcinoma of the prostate who have elected to proceed with radical prostatectomy as primary curative therapy Subjects having no prior administration of lithium or lithium containing medications within 90 days of study enrollment Subjects >/= 18 years of age ECOG (Eastern Cooperative Oncology Group) performance status of </= 1 Adequate renal function defined as GFR (Glomerular Filtration Rate) >/= 50 mL/min Use of adequate contraception ECG (Electrocardiogram) within normal limits Subjects must agree not to take any new vitamin supplements or herbal remedy during the study period Subjects must be able to safety take lithium carbonate for at least 4 weeks before scheduled prostatectomy  Subjects who have received any investigational medication within 30 days of first lithium dose Subjects currently receiving, or who have had previous hormonal, chemotherapy or radiotherapy for prostate cancer Subjects with known brain metastases History of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate Uncontrolled intercurrent illness such as ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Schizophrenia Metabolic Syndrome Vitamin D Deficiency • Men and women with a DSM-IV clinical diagnosis of Schizophrenia, Schizoaffective or Bipolar disorder to 65 years of age; male and female A willingness and ability to provide signed informed consent The subject should have been on quetiapine 100 mg or more for more than 12 weeks  Pregnant women Subjects considered at high suicide risk based on the MINI Suicidality Module (> 17 points) Unstable general medical condition or serious illness (e.g. death or hospitalization is anticipated within one year), poor kidney function or liver function (defined as laboratory values ≥ three times the upper limit of the normal), and seizure disorders except for childhood seizure disorders Concurrent therapy with certain psychotropics is permitted, provided that the medication and dose have been stable for the past 90 days Patients on concomitant treatment with clozapine and olanzapine are not permitted Patients on immunosuppressant medications or any orexigenic or anorexigenic drug Patients on concomitant treatment with amphetamines and/ or methylphenidate History of hypothyroidism or thyroxine therapy Patients with a known condition or undergoing therapeutic measures that affects weight, including but not limited to: eating disorder, type I diabetes, hyperthyroidism, thyroxine therapy, Topamax therapy, and infectious diseases, such as HIV, hepatitis B, and hepatitis C Active supplementation of vitamin D within the last 3 months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorder major depressive episode in type2 bipolar disorder or bipolar disorder NOS.(MADRS more than 20 point) ears to 65years subjects who sign the informed consent document  don't have Diabetes and abnormal metabolism of sugar not noticed as bipolar disorder have an organic brain disease pregnant or breastfeeding women don't have heart disease have actively suicidal thought(Suicidal ideation score of MADRS is 6) who are judged by the investigator to should be excluded from the study
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorder Suicidal Ideation Depression Meets DSM-IV for BD I and II current depressive episode Able to give written informed consent Age > to 18 years and < 65 years Currently suicidal as defined by a MADRS suicide item score of > 3 or previous history of serious suicidal ideation that required hospitalization All subjects need to have normal hearing and normal/corrected-to-normal vision  Medical illness or non-psychiatric medical treatment that would likely interfere with study participation Neurologic disorder, previous ECT, or history of head trauma (i.e. known structural brain lesion potentially confounding MRI results) Substance abuse within the past 3 months or current substance dependence (confirmed by MINI) Left-handedness Contraindications to MRI (metallic implants, claustrophobia, etc.) Subjects who need urgent psychiatric care requiring hospitalization (evaluated by clinicians)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-50.0,  Healthy Be in good general health as determined by the investigator Have a 3-month history of a normal nightly sleep pattern based on the subject's self report  A usual time in bed A regular bedtime between 2200 and 2400 hours No habitual daytime napping Epworth Sleepiness Scale score ≤ 10 Be able to read, understand, and provide written/dated informed consent before enrolling in the study, and must be willing and able to comply with all study procedures Be able to follow verbal and written instructions provided in English  Have a body mass index (BMI) >35 kg/m2 Have symptoms consistent with the diagnosis of any sleep disorder (e.g., insomnia, sleep apnea, narcolepsy, periodic leg movements, or restless leg syndrome) On screening PSG AHI > 10 or PLMAI >10 Have a known or suspected diagnosis of Acquired Immune Deficiency Syndrome (AIDS), or have tested seropositive for human immunodeficiency virus (HIV) antibody or antigen previously Have any clinically significant abnormal finding in physical examination, neurological assessment, vital signs, elevated body temperature, or clinical laboratory tests, as determined by the Investigator Have a known exaggerated pharmacological sensitivity, hypersensitivity, or history of a clinically significant adverse reaction to zolpidem Have a known or exaggerated pharmacological sensitivity, hypersensitivity, or intolerance to doxepin HCl, any tricyclic antidepressant, or antihistamine Currently taking cimetidine or a monoamine oxidase inhibitor (MAOI) Current diagnosis of severe urinary retention Current diagnosis of untreated glaucoma
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Diabetes Weight Gain Weight Loss Cardiovascular Disease Obesity Participants will be men of European (self-report of both parents of white European origin) or South Asian (self-report of both parents of Indian, Pakistani, Bangladeshi or Sri Lankan origin) with BMI <25 kg.m-2, who have been weight stable (± 2 kg) for >6 months  will diabetes (physician diagnosed or HbA1c ≥6.5% on screening), history of cardiovascular disease, regular participation in vigorous physical activity, current smoking, taking drugs or supplements thought to affect carbohydrate or lipid metabolism, or other significant illness that would prevent full participation in the study
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cirrhosis Age 18 to 70 years Clinical, Biochemical, Radiological ,Histological evidence of cirrhosis of all etiology Child A and B cirrhosis Cirrhosis patients giving h/o persistent sleep disturbances  Active alcohol intake or intake within 1 month of enrollment Active substance abuse or intake within 1 month of enrollment Known psychiatric and neurological disorders Patient using antidepressant, anticonvulsants, other hypnotics Pregnancy or lactation Overt hepatic encephalopathy Child C cirrhosis Acute decompensated state of CLD (Chronic Liver Disease) GastroIntestinal bleed, increased jaundice, HE (Hepatic Encepahlopahty) , SBP (Spontaneous Bacterial Peritonitis) HCC (HepatoCellular Carcinoma) with portal vein thrombosis
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Bipolar Disorder Age 18 or older If Pregnant, equal to or less than 26 weeks English-speaking DSM-IV Bipolar Disorder, any subtype, Major Depressive Disorder, or Mood Disorder Not Otherwise Specified Able to provide informed consent Daily dosing of lithium  Active substance abuse within last 6 months and/or positive urine drug screen Active suicidality No obstetrical care Use of other drugs that affect metabolism of lithium Medications in FDA categories F or X that are not antimanic drugs Chronic Kidney Disease
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Agitation Male and female patients between the ages of 18-65 years, inclusive Patients (or legal representative) willing and able to provide written Informed Consent Form Psychiatric patients already diagnosed of schizophrenia or bipolar disorder, according to the Diagnostic and Statistical Manual of Mental Disorders IV, Diagnostic and Statistical Manual of Mental Disorders V or International Code of Disease criteria Patients with an on-going agitation episode, or with a previous one within the 6 months prior to screening, attended and managed in the hospital setting Previously treated with with a positive outcome (responders) according to (CGI-I) scale (defined as having a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) Patients free of active respiratory disease such as acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (asthma, chronic obstructive pulmonary disease or emphysema) Requirement of family or other caregiver support at study investigator (defined as a patient's relative or caregiver (male or female) ≤ 80 year old, who spend ≥ 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures) Availability of patient's medical records data about the previous treatment with at hospital setting  Patient diagnosed with dementia Patients with serious and unstable illnesses including current hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis) Patients with a history of allergic reactions to loxapine or amoxapine Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Insomnia Bipolar Disorder Adult outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) for bipolar I disorder (296.70), bipolar II disorder (296.89), or bipolar disorder not otherwise specified (296.80), with concurrent insomnia related to bipolar disorder (307.42) Currently taking ≥ 1 prescription psychotropic medication (hypnotic agents, anxiolytics, atypical antipsychotics, mood stabilizers, and/or antidepressants) for management of bipolar disorder Subjective total sleep time (sTST) < 6 hours on ≥ 1 night during the prior week  Current hypo/manic symptoms, as evidenced by YMRS total score ≥ 12 Current (past 6 months) alcohol or substance use disorder Current psychosis Patients who are actively suicidal or evaluated as being a high suicide risk Women who are currently pregnant or breastfeeding Clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, CBC with differential, thyroid stimulating hormone) Presence of any unstable and/or potentially confounding neurological and/or medical disorder